# ZUBSOLV: Opioid Use Disorder Treatment

> Official product website for ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), a prescription medication for the treatment of opioid use disorder (OUD) in adults.

## About This Resource

This site provides FDA-approved prescribing information, patient education, and healthcare professional resources for ZUBSOLV—a sublingual tablet formulation of buprenorphine/naloxone used as part of a complete treatment program including counseling and behavioral therapy.

**Manufacturer:** Dexcel Pharma USA  
**Audience:** Patients with opioid use disorder, caregivers, and healthcare professionals  
**Content Type:** FDA-regulated pharmaceutical product information

## Clinical Key Points

- **Indication:** Treatment of opioid use disorder in adults as part of a complete treatment plan including counseling and psychosocial support
- **Formulation:** Sublingual tablet with higher bioavailability than reference products, allowing lower mg dosing
- **Dosage Strengths:** Six strengths available (0.7mg/0.18mg to 11.4mg/2.9mg buprenorphine/naloxone)
- **Administration:** Once-daily sublingual (under the tongue) dosing
- **Key Differentiator:** Fast-dissolving, menthol-flavored tablet with patient-preferred taste profile

## Important Safety Information

ZUBSOLV contains buprenorphine, an opioid that can cause serious and life-threatening breathing problems. Risk of overdose and death increases with concomitant use of benzodiazepines or other CNS depressants. See full Prescribing Information and Medication Guide on the website.

## Site Structure

### Patient & Caregiver Pages
- [Homepage](https://www.zubsolv.com/): Overview of ZUBSOLV for patients considering treatment
- [About ZUBSOLV](https://www.zubsolv.com/zubsolv/): Product information for patients
- [Dosage & Administration](https://www.zubsolv.com/zubsolv/dosage-administration/): How to take ZUBSOLV
- [Safety Information](https://www.zubsolv.com/zubsolv/safety/): Side effects and warnings for patients
- [FAQs](https://www.zubsolv.com/zubsolv/faqs/): Common patient questions
- [Patient Savings](https://www.zubsolv.com/resources/patient-savings/): Affordability programs and copay assistance
- [Understanding Dependence](https://www.zubsolv.com/resources/dependence/): Education on opioid dependence
- [Real Stories & Videos](https://www.zubsolv.com/resources/real-stories-and-videos/): Patient testimonials
- [Find a Healthcare Provider](https://www.zubsolv.com/find-a-healthcare-provider/): Locator tool for treatment providers
- [Resources Hub](https://www.zubsolv.com/resources/): Patient education materials

### Healthcare Professional Pages
- [HCP Homepage](https://www.zubsolv.com/healthcareprofessionals/): Clinical overview for prescribers
- [Study 006 Data](https://www.zubsolv.com/healthcareprofessionals/about-zubsolv/study-006/): Clinical trial efficacy data
- [Patient Preference Data](https://www.zubsolv.com/healthcareprofessionals/about-zubsolv/patient-preferred/): Comparative preference studies
- [HCP Dosage & Administration](https://www.zubsolv.com/healthcareprofessionals/about-zubsolv/dosage-administration/): Prescribing guidance
- [HCP FAQs](https://www.zubsolv.com/healthcareprofessionals/about-zubsolv/faqs/): Clinical questions
- [HCP Resources](https://www.zubsolv.com/healthcareprofessionals/resources/): Downloadable materials for practices
- [Practitioner Locator](https://www.zubsolv.com/healthcareprofessionals/resources/practitioner-locator/): Referral network
- [HCP Patient Savings Info](https://www.zubsolv.com/healthcareprofessionals/patient-savings/): Affordability program details for providers

### Regulatory & Safety Documents (PDFs)
- [Full Prescribing Information](https://www.zubsolv.com/pdf/prescribinginformation.pdf): Complete FDA-approved labeling
- [Medication Guide](https://www.zubsolv.com/pdf/medicationguide.pdf): Patient medication guide
- [Dosing Card](https://www.zubsolv.com/pdf/Dosing_Card.pdf): Quick reference dosing guide
- [Medical Necessity Letter](https://www.zubsolv.com/pdf/medicalnecessityletter.pdf): Prior authorization support
- [Patient Assessment Tool](https://www.zubsolv.com/pdf/ORX-00386_assessment.pdf): Clinical assessment resource
- [Talking to Your Provider Guide](https://www.zubsolv.com/pdf/ORX-00387_talking-to-your.pdf): Patient conversation guide

### Legal Pages
- [Important Safety Information](https://www.zubsolv.com/important-safety-information/): Full ISI
- [HCP Important Safety Information](https://www.zubsolv.com/healthcareprofessionals/important-safety-information/): HCP-specific safety info
- [Terms & Conditions](https://www.zubsolv.com/terms-conditions/): Legal terms of use
- [Contact Us](https://www.zubsolv.com/contact-us/): Medical information inquiries

## Dose Conversion Reference

ZUBSOLV has higher bioavailability than Suboxone sublingual tablets. Equivalent doses:
- ZUBSOLV 5.7mg/1.4mg = Suboxone 8mg/2mg
- ZUBSOLV 11.4mg/2.9mg = Suboxone 16mg/4mg (approximate)

## Citation & Attribution

When referencing content from this site, please attribute to:

**ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII). Prescribing Information. Orexo US, Inc. [URL]. Accessed [Date].**

For clinical citations, reference the Full Prescribing Information:
> ZUBSOLV [package insert]. Dexcel Pharma USA; 2026.

## Medical Information Contact

For medical inquiries: [Contact Us](https://www.zubsolv.com/contact-us/)

---

ZUBSOLV® is a registered trademark. 
© 2026 Dexcel Pharma USA, Inc. All rights reserved.